Aytu biopharma reports first quarter 2022 financial results

Quarterly net revenue increased 62% to $21.9 million ended quarter with approximately $40.6 million in cash, cash equivalents and restricted cash fully integrated and expanding rxconnect patient support program and salesforce drove growth across prescription portfolio planned pivotal study for ar101 in vascular ehlers-danlos syndrome (veds) to begin in 1h22 initiation of healight randomized, sham-controlled study by year-end 2021 management to host live conference call and webcast today at 4:30 p.m. et englewood, co / accesswire / november 15, 2021 / aytu biopharma, inc. (nasdaq:aytu), a specialty pharmaceutical company focused on commercializing novel therapeutics and consumer healthcare products, today reported financial results for its fiscal first quarter 2022 ended september 30, 2021.
AYTU Ratings Summary
AYTU Quant Ranking